Recombinant adeno-associated (rAAV) vector-based gene therapy has been the focus of intense research driven by the safety profile and several recent clinical breakthroughs. As of April 2021, there are two rAAV-based gene therapies approved and more than two-hundred active clinical trials (approximately thirty in Phase III). However, the expected increase in demand for rAAV vectors still poses several challenges. Discussed herein are key aspects related to R&D needs and Chemistry, Manufacturing and Control (CMC) efforts required to attend this growing demand. Authors provide their perspective on strategic topics for rAAV-based therapies success: scalability and productivity; improved safety; increased process understanding combined with development of orthogonal bioanalytics that are able to identify, monitor and control Critical Quality Attributes (CQAs) during bioprocessing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.copbio.2021.12.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potency by design: Novel insights in transfection and purification for manufacturing of rAAV gene therapy vectors.
J Biotechnol
December 2024
Gene Therapy Process Development, Baxalta Innovations GmbH, part of Takeda companies, Orth an der Donau, 2304 Orth an der Donau, Austria. Electronic address:
This study investigates the crucial role of transfection methods in the manufacturability and potency of recombinant adeno-associated virus (rAAV) gene therapies. By employing a novel analytical approach, multiplex digital PCR (dPCR), we evaluated the impact of different transfection reagents and conditions on the scalability and quality of rAAV. Our research demonstrates that the selection of transfection approach significantly influences not only the yield and ease of scale-up but also the potency of the final product.
View Article and Find Full Text PDFDNA contamination within recombinant adeno-associated virus preparations correlates with decreased CD34 cell clonogenic potential.
Mol Ther Methods Clin Dev
December 2024
Department of Microbiology, Immunology, and Molecular Genetics, UCLA, Los Angeles, Los Angeles, CA, USA.
Recombinant adeno-associated viruses (rAAV) are promising for applications in many genome editing techniques through their effectiveness as carriers of DNA homologous donors into primary hematopoietic stem and progenitor cells (HSPCs), but they have many outstanding concerns. Specifically, their biomanufacturing and the variety of factors that influence the quality and consistency of rAAV preps are in question. During the process of rAAV packaging, a cell line is transfected with several DNA plasmids that collectively encode all the necessary information to allow for viral packaging.
View Article and Find Full Text PDFLeverage of nuclease-deficient CasX for preventing pathological angiogenesis.
Mol Ther Nucleic Acids
September 2023
The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China.
Article Synopsis
- Scientists are using a new method called CRISPR to help treat eye diseases by blocking a specific part of a gene that causes problems with blood vessel growth in the eye.
- They found a way to use a small virus that delivers this CRISPR tool directly to the eye cells that are misbehaving.
- In tests on mice, they showed that this method successfully reduced the bad gene's activity and could stop harmful blood vessel growth in the retina.
Leveraging rAAV bioprocess understanding and next generation bioanalytics development.
Curr Opin Biotechnol
April 2022
iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2780-901, Portugal; ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. Da República, Oeiras, 2780-157, Portugal. Electronic address:
Recombinant adeno-associated (rAAV) vector-based gene therapy has been the focus of intense research driven by the safety profile and several recent clinical breakthroughs. As of April 2021, there are two rAAV-based gene therapies approved and more than two-hundred active clinical trials (approximately thirty in Phase III). However, the expected increase in demand for rAAV vectors still poses several challenges.
View Article and Find Full Text PDFDeep Parallel Characterization of AAV Tropism and AAV-Mediated Transcriptional Changes Single-Cell RNA Sequencing.
Front Immunol
December 2021
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States.
Engineered variants of recombinant adeno-associated viruses (rAAVs) are being developed rapidly to meet the need for gene-therapy delivery vehicles with particular cell-type and tissue tropisms. While high-throughput AAV engineering and selection methods have generated numerous variants, subsequent tropism and response characterization have remained low throughput and lack resolution across the many relevant cell and tissue types. To fully leverage the output of these large screening paradigms across multiple targets, we have developed an experimental and computational single-cell RNA sequencing (scRNA-seq) pipeline for characterization of barcoded rAAV pools at high resolution.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!